Molecular detection of t(8;21)/AML1‐ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype

The t(8;21) identifies a subgroup of acute myeloid leukaemia (AML) with a relatively good prognosis which may merit different treatment. It is associated predominantly, but not exclusively, with AML M2, and corresponds to rearrangements involving the AML1 and ETO genes. AML1‐ETO positive, t(8;21) negative cases are well recognized but their incidence is unknown. In order to determine optimal prospective AML1‐ETO RT‐PCR screening strategies, we analysed 64 unselected AML M1 and M2 cases and correlated the results with other biological parameters. Molecular screening increased the overall detection rate from 8% to 14%. AML1‐ETO was found in 3% (1/32) of AML M1 and 25% (8/32) of M2, including three patients without a classic t(8;21) but with chromosome 8 abnormalities. It was more common in younger patients. Correlation with morphology enabled development of a scoring system which detected all nine AML1‐ETO‐positive cases with a false positive rate of 7% (4/55). Although certain AML1‐ETO‐positive cases demonstrated characteristic immunological features (CD19 and CD34 expression, CD33 negativity), each of these markers was insufficiently specific to permit prediction in an individual case. We conclude that initial routine prospective molecular screening for AML1‐ETO in all AMLs, combined with standardized morphological and immunological analysis, is desirable in order to produce improved prognostic stratification and to determine whether screening can ultimately be restricted to appropriate subgroups.

[1]  A. Hagemeijer,et al.  Interphase cytogenetics of the t(8;21)(q22;q22) associated with acute myelogenous leukemia by two-color fluorescence in situ hybridization. , 1995, Cancer genetics and cytogenetics.

[2]  A. Hagemeijer,et al.  Identical fusion transcript associated with different breakpoints in the AML1 gene in simple and variant t(8;21) acute myeloid leukemia. , 1995, Leukemia.

[3]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[4]  Y. Yamaguchi-Iwai,et al.  Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[6]  T. Smetsers,et al.  Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia. , 1994, Leukemia.

[7]  J. Rowley,et al.  Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21). , 1994, Leukemia.

[8]  R. Berger,et al.  AML-1 gene rearrangement and AML-1-ETO gene expression as molecular markers of acute myeloblastic leukemia with t(8;21). , 1994, Leukemia.

[9]  J. Friedl,et al.  AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. , 1994, Leukemia.

[10]  E. Estey,et al.  Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. , 1994, Leukemia.

[11]  N. Kamada,et al.  Cellular characteristics of acute myeloblastic leukemia associated with t(8;21)(q22;q22). The Japanese Cooperative Group of Leukemia/Lymphoma. , 1994, Leukemia & lymphoma.

[12]  A. Cork,et al.  Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia. , 1993, Cancer research.

[13]  Y. Ito,et al.  PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Ohki,et al.  The t(8;21) translocation in acute myeloid leukemia results in production of an AML1‐MTG8 fusion transcript. , 1993, The EMBO journal.

[15]  G. Wang,et al.  Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. , 1993, Oncogene.

[16]  E. Paietta,et al.  Immunophenotypic features of t(8;21) (q22;q22) acute myeloid leukemia in adults. , 1993, Blood.

[17]  P. Ternes,et al.  An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. , 1993, BioTechniques.

[18]  F. Calabi,et al.  Translocation breakpoints are clustered on both chromosome 8 and chromosome 21 in the t(8;21) of acute myeloid leukemia. , 1993, Blood.

[19]  M. Ohki,et al.  The 8;21 chromosome translocation in acute myeloid leukemia is always detectable by molecular analysis using AML1. , 1993, Blood.

[20]  M. Ohki,et al.  Consistent disruption of the AML1 gene occurs within a single intron in the t(8;21) chromosomal translocation. , 1992, Cancer research.

[21]  F. Behm,et al.  Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. , 1992, Blood.

[22]  P. Watkins,et al.  Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. , 1992, Cancer genetics and cytogenetics.

[23]  R. Neiman,et al.  Acute leukemia with t(8;21) can express T-lineage-associated markers. , 1992, Blood.

[24]  H. Drabkin,et al.  Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. , 1992, Blood.

[25]  T. Kyo,et al.  Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. , 1992, Blood.

[26]  F. Mitelman,et al.  Quantitative acute leukemia cytogenetics , 1992, Genes, chromosomes & cancer.

[27]  S. Kawano,et al.  Expression of CD7 antigen precludes t(8;21)(q22;q22) chromosome aberration in acute myeloblastic leukemia. , 1992, Blood.

[28]  N. Speck,et al.  Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. , 1992, Molecular and cellular biology.

[29]  M. Ohki,et al.  t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Cleary,et al.  The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. , 1991, Blood.

[31]  Groupe Français de Cytogénétique Hématologique.  Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Français de Cytogénétique Hématologique. , 1990, Cancer genetics and cytogenetics.

[32]  R. Beuscart,et al.  Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.

[33]  F. Behm,et al.  Cytogenetics of childhood acute nonlymphocytic leukemia. , 1989, Cancer genetics and cytogenetics.

[34]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[35]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[36]  D. Swirsky,et al.  8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features , 1984, British journal of haematology.

[37]  F. Sigaux,et al.  Cytologic characterization and significance of normal karyotypes in t(8;21) acute myeloblastic leukemia. , 1982, Blood.

[38]  A. Cork,et al.  Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. , 1979, Blood.

[39]  M. Ohki,et al.  t ( 8 ; 21 ) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene , AMLJ ( chromosomal translocation / cancer genetics , 2022 .